Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for CNP in PDR and CRVO
NCT01724554Phase 2Completed
- Sponsor
- Ophthalmic Consultants of Boston
- Start
- Nov 2012
- Primary completion
- Oct 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in proliferative diabetic retinopathy (PDR), central retinal vein occlusion (CRVO), sponsored by Ophthalmic Consultants of Boston. Started Nov 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT01724554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01724554.